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Summary
Despite the existence of tumor-specific immune cells, most tumors have devised strategies to avoid immune attack. We
demonstrate here that galectin-1 (Gal-1), a negative regulator of T cell activation and survival, plays a pivotal role in
promoting escape from T cell-dependent immunity, thus conferring immune privilege to tumor cells. Blockade of immuno-
suppressive Gal-1 in vivo promotes tumor rejection and stimulates the generation of a tumor-specific T cell-mediated
response in syngeneic mice, which are then able to resist subsequent challenge with wild-type Gal-1-sufficient tumors.
Our data indicate that Gal-1 signaling in activated T cells constitutes an important mechanism of tumor-immune escape
and that blockade of this inhibitory signal can allow for and potentiate effective immune responses against tumor cells,
with profound implications for cancer immunotherapy.
Introduction positive T lymphocytes (Hahne et al., 1996; O’Connell et al.,
2001; Andreola et al., 2002; Whiteside, 2002). However, despite
A long-standing paradox in tumor immunology is the growth the wealth of data accumulated in support of the FasL counterat-
of antigenic tumors in spite of demonstrable antitumor T cell tack hypothesis, many contradictory studies have been reported
responses (Pardoll, 2002; Smyth et al., 2001). Recent progress showing that FasL can also have proinflammatory and antitu-
toward an improved understanding of the interactions between moral effects in some contexts (Restifo, 2001; Simon et al.,
tumor cells and the host’s immune system has led to the realiza- 2002). To reconcile these conflicting findings, it has been hy-
tion that tumor cells have devised multiple strategies to evade pothesized that the maintenance of immune privilege in tumors
immune attack (Marincola et al., 2000; Trapani, 2002; Uytten- relies not only on FasL itself but also on the collective production
hove et al., 2003; Igney and Krammer, 2002). Evasion mecha- of as yet unidentified immunosuppressive factors (Green and
nisms can either be preexisting, arise through outgrowth of Ferguson, 2001; O’Connell et al., 2001). These inhibitory signals
escape mutants, or take place during tumor-sculpting actions by may create an appropriate setting that will prevent the proin-
the immune system, in accordance with the recently proposed flammatory effects of FasL, thus favoring immune escape by
“cancer immunoediting” hypothesis (Dunn et al., 2002). eliminating antitumor effector cells. Accordingly, it has been
suggested that the final outcome of an effective antitumor re-One of the most studied strategies of tumor-immune escape
is represented by the acquisition of FasL expression that may sponse is determined by a delicate interplay among activating
and inhibitory regulatory pathways and that removal of inhibitoryenable cancer cells to deliver death signals to activated Fas-
S I G N I F I C A N C E
In recent years, one of the most important insights into tumor immunity was provided by the identification of negative regulatory
pathways and immune escape strategies that, by counteracting tumor effector mechanisms, greatly influence the magnitude of
antitumor responses. Galectin-1, a -galactoside binding protein with immune regulatory functions, is expressed by many different
tumor types, and its expression correlates with the aggressiveness of these tumors and the acquisition of metastatic phenotypes.
Here we provide evidence both in vitro and in vivo showing that Gal-1 contributes to immune privilege of tumors by modulating
survival and polarization of effector T cells. More importantly, our data highlight a potential molecular target for manipulation of
T cell tolerance and apoptosis with profound implications for cancer immunotherapy.
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signals may be a particularly useful adjunct to other therapeutic pressed Gal-1 (Figure 1A), although particularly high expression
was detected in murine B16 and human Mel-J and Mel-LESapproaches for cancer (Pardoll, 2002; Phan et al., 2003; Cheng
cell lines. Immunofluorescence staining followed by confocalet al., 2003).
microscopy or flow cytometry revealed a predominant cyto-Galectins, a growing family of carbohydrate binding pro-
plasmic and nuclear localization of this protein, although specificteins, have recently attracted the attention of immunologists as
labeling was also observed at the cell surface of human andnovel regulators of immune cell homeostasis (Liu, 2000). Despite
murine melanoma cells (Figures 1B and 1C). In addition, weextensive sequence homology and similar carbohydrate speci-
detected the presence of Gal-1 in concentrated serum-free con-ficity, various members of this protein family behave as amplifi-
ditioned media (SFCM) from different tumor cell lines (Figureers of the inflammatory response, while others activate homeo-
1D). To confirm its identity, we purified this protein from SFCMstatic signals that serve to shut off immune effector functions
of two different cell lines (Mel-J and Mel-LES) by size exclusion(Rabinovich et al., 2002a). Recently, it has become clear that
and affinity chromatography. Amino acid sequence analysis of
galectin-1 (Gal-1), a prototype member of this protein family,
selected trypsin-digested peptides revealed the complete iden-
has the potential to inhibit T cell effector functions by promoting tity of the isolated protein with human placental Gal-1 (see
growth arrest and apoptosis of activated T cells (Blaser et al., Supplemental Figure S1 at http://www.cancercell.org/cgi/
1998; Perillo et al., 1995; Rabinovich et al., 1998, 2002b), induc- content/full/5/3/241/DC1). Because tumor cell lines grown in
ing partial T cell activation (Chung et al., 2000) and/or blocking vitro may not reflect the real state of tumor cells in vivo, we
proinflammatory cytokine secretion (Rabinovich et al., 1999a, also tested expression of Gal-1 in human tumor samples. West-
1999b). In vivo, therapeutic administration of Gal-1 suppresses ern blot analysis and immunohistochemistry demonstrated high
T helper (TH)-1-dependent chronic inflammation in experimental expression of this protein in freshly isolated tumors from mela-
models of autoimmunity by increasing T cell susceptibility to noma patients (Figures 1E and 1F).
activation-induced cell death and skewing the balance of the To investigate the possibility that expression of Gal-1 may
immune response toward a TH2 profile (Rabinovich et al., 1999a; confer immune privilege to tumor cells, we transfected B16
melanoma cells with Gal-1 antisense cDNA and established 12Santucci et al., 2003).
different knockdown clones with low or intermediate Gal-1 levelsExpression of Gal-1 has been well documented in immune
from the heterogeneous population of stably transfected mela-privileged organs (Rabinovich, 1999) and in many different tumor
noma cells. Based on Gal-1 expression, we then selected repre-types including astrocytoma (Camby et al., 2001) and prostate
sentative clones for in vitro and in vivo assays. Western blot(van den Brule et al., 2001), thyroid (Xu et al., 1995), colon
analysis of supernatants collected from knockdown transfec-(Sanjuan et al., 1997), bladder (Cindolo et al., 1999), and ovary
tants revealed decreased levels of Gal-1 secretion (Figure 2A).(van den Brule et al., 2003) carcinomas. Interestingly, such ex-
Clone one (B16/C1) showed the lowest Gal-1 levels, represent-pression correlates with the aggressiveness of these tumors
ing a relative decrease of 93% compared to cells transfected
and the acquisition of metastatic phenotype.
with empty vector (B16/), while clones two and three (B16/
On the basis of these data, we hypothesized that tumor C2 and B16/C3) showed intermediate Gal-1 levels, representing
cells may impair T cell effector functions by secretion of Gal-1 relative decreases of 65% and 59%, respectively.
and that this mechanism may contribute in tilting the balance To evaluate the contribution of Gal-1 to the immunosuppres-
toward an immunosuppressive environment at the tumor site. sive and proapoptotic activity of these tumor cell supernatants,
Our data provide evidence both in vitro and in vivo of the rele- we next incubated activated splenocytes from C57BL/6 (B6)
vance of Gal-1-mediated immunosuppression as a novel mech- normal mice for 18 hr with SFCM obtained from control or Gal-1
anism of tumor-immune escape, indicating that blockade of this knockdown transfectants and analyzed the apoptotic T cell pop-
pathway has strong therapeutic potential to shift the balance ulation by double staining using FITC-annexin V and PE-conju-
in favor of an efficient T cell-mediated antitumor immune re- gated anti-CD3 monoclonal antibody (mAb). Supernatants col-
lected from control B16/ cells induced high levels of T cellsponse. To the best of our knowledge, this is the first in vivo
apoptosis (71.0%  3.2%), whereas SFCM collected fromstudy demonstrating a link between Gal-1-mediated immuno-
knockdown transfectants expressing the lowest Gal-1 levelsregulation and immune privilege in a setting relevant to cancer
(B16/C1) induced only 27.3%  2.8% of annexin V staining.immunotherapy.
Remarkably, splenocytes incubated in the presence of SFCM
obtained from B16/C2 and B16/C3 underwent apoptotic cell
Results
death at intermediate levels (40.1% 3.9% and 50.8% 3.3%,
respectively) (Figure 2B). These results indicate a functional
Identification of Gal-1 as a major immunosuppressive correlation between the levels of Gal-1 in B16 culture superna-
factor secreted by human and murine tants and the extent of tumor-induced T cell death.
melanoma cells To validate this finding in a human setting, we activated
Using a specific anti-Gal-1 antibody (Ab), we screened a panel peripheral blood mononuclear cells (PBMCs) with phytohemag-
of six human and murine melanoma cell lines for Gal-1 expres- glutinin (PHA) and then cultured for 18 hr in the presence of
sion. We selected melanoma as a tumor model on the basis of different concentrations of SFCM from Mel-LES or Mel-J mela-
previous findings reporting the isolation of a low molecular noma cell lines (Figure 2C). Activated T cells exposed to Mel-
weight (14 kDa) immunosuppressive factor from human mela- LES SFCM showed an average of 75.2%  4.1% annexin V
noma cell supernatants (Morvillo et al., 1996), whose biochemi- staining. Remarkably, when SFCM was preincubated with a
cal and functional properties closely resembled those of Gal-1. neutralizing anti-Gal-1 IgG (Fab)2, the percentage of apoptotic
T cells decreased to 34.2%  5.6%, whereas addition of aWestern blot analysis showed that all melanoma cell lines ex-
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Figure 1. Expression and secretion of Gal-1 by hu-
man and murine melanoma cells
A: Western blot detection of Gal-1 (14.5 kDa) in
total cell lysates (15 g) from human and murine
melanoma cell lines using an affinity-purified
anti-Gal-1 Ab. Blots incubated with preimmune
IgG were used as negative controls.
B: Indirect immunofluorescence staining and
confocal microscopy after permeabilization of
a representative human melanoma cell line
(MEL-J) (Scale bar, 70 m).
C: Flow cytometry of nonpermeabilized Mel-J
and B16 cell lines using an anti-Gal-1 Ab (dark
histogram) or control rabbit IgG (empty histo-
gram).
D: Western blot detection of concentrated se-
rum-free conditioned medium (SFCM) (15 g)
from different melanoma cell lines.
E: Western blot analysis of total cell lysates from
representative samples obtained from human
melanoma patients.
F: Immunoperoxidase staining of a paraffin-
embedded tissue section of a representative hu-
man melanoma specimen using an anti-Gal-1
Ab or the same dilution of a control rabbit IgG
(magnification, 40; inset, 100). Scarce
amounts of Gal-1 were detected in normal hu-
man melanocytes (data not shown).
control rabbit IgG (Fab)2 had no effect (data not shown). We 3B). To rule out the possibility that stable transfection with anti-
also observed a similar reduction in the frequency of annexin sense Gal-1 may directly affect tumor cell growth, we analyzed
V positive cells when thiodigalactoside (TDG, a galectin-specific the in vitro cell proliferation of B16/ and Gal-1 knockdown
sugar inhibitor) was incorporated to the culture medium. We clones. All transfectants exhibited a similar growth rate (Figure
confirmed these findings by propidium iodide staining of sub- 3C), indicating no growth advantage of B16/ over antisense-
diploid nuclei (see Supplemental Figure S2 at http://www. transfected tumor cells. In addition, all tumor transfectants grew
cancercell.org/cgi/content/full/5/3/241/DC1). In addition, hu- progressively at the same rate in immunodeficient nude mice
man PBMCs simultaneously exposed to PHA and the indicated (data not shown).
stimuli for 72 hr showed a similar outcome in a cell proliferation These results demonstrate that targeted inhibition of Gal-1
assay (Figure 2D). expression renders mice resistant to tumor challenge and indi-
Taken together, these results demonstrate that both murine cate a functional correlation between Gal-1 levels in tumor cells
and human melanoma cells secrete functional Gal-1, which sub- and the extent of in vivo tumor rejection.
stantially contributes to the immunosuppressive and proapo-
ptotic activities of these tumor cells.
Tumor rejection induced by Gal-1 blockade requires
intact CD4 and CD8 T cell responsesTargeted inhibition of Gal-1 gene expression renders
In order to investigate the involvement of the immune systemmice resistant to tumor challenge
in the tumor rejection effect induced by Gal-1 blockade, weTo investigate whether tumor cells may overwhelm the antitumor
depleted CD4, CD8, or NK1.1 cells in vivo and challengedT cell responses in vivo through Gal-1-dependent mechanisms,
mice with knockdown transfectants. Depletion of either CD4we explored the impact of Gal-1 blockade on tumor progression
or CD8 T cells partially restored B16/C1 cell growth in B6by injecting B6 mice with representative B16 knockdown
mice (Figures 4A and 4B). Remarkably, depletion of both T celltransfectants. All mice (n  21) injected subcutaneously with
subsets completely abrogated resistance to tumor challenge2  105 B16/ transfectants developed progressively growing
induced by Gal-1 blockade and resulted in rapid tumor progres-tumors at a rate similar to that of nontransfected B16 cells,
sion and similar growth rate as mice injected with B16/leading to uniform terminal morbidity by about 20–25 days post-
transfectants (Figures 4A and 4B). On the other hand, depletioninoculation (Figures 3A and 3B). Remarkably, B16/C1 tumor
of NK1.1 cells had only a marginal effect in 3 out of 15 micetransfectants, expressing the lowest Gal-1 levels, were rejected
tested (Figure 4A). Furthermore, pretreatment of mice with con-rapidly and almost completely, since only 2 of 27 mice showed
trol mouse IgG did not alter the tumor rejection effect inducedtumor growth by day 40. Furthermore, administration of B16/
by Gal-1 blockade (data not shown). These results support theC2 and B16/C3 transfectants resulted in substantially delayed
concept that the generation of antitumor activity in the absencetumor growth in all mice, in comparison with B16/ cells (Figure
of Gal-1 requires participation of both CD4 and CD8 T cell3A). As expected, mice inoculated with B16/C1 knockdown
transfectants remained tumor free for about 35 days (Figure subsets.
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Figure 2. Identification of Gal-1 as a major immunosuppressive and proapoptotic protein secreted by human and murine melanoma cells
A: Western blot and densitometric analysis of SFCM (15 g) from knockdown (B16/C1, C2, C3) or control (B16/) transfectants using an anti-Gal-1 Ab.
B: Splenocytes from B6 mice were activated with Con A for 72 hr and then cultured for 18 hr in the presence of SFCM collected from control (B16/) or
knockdown transfectants expressing low (B16/C1) or intermediate (B16/C2, B16/C3) Gal-1 levels. T cell apoptosis was assessed by double staining with FITC-
annexin V and PE-anti-CD3 mAb. Proportion of annexin V-positive cells is shown in histograms as percentage of a representative out of three independent
experiments (p  0.01 B16/C1 versus B16/; p  0.05 B16/C2 and B16/C3 versus B16/ Student’s t test).
C: Human PBMCs were activated with PHA for 72 hr and then cultured for 18 hr with SFCM from Mel-J in the absence or presence of a neutralizing anti-
Gal-1 (Fab)2 (10 g/ml) or 30 mM thiodigalactoside (TDG). Positive controls of apoptosis were analyzed in parallel by incubating activated T cells with
increasing doses of rGal-1. T cell apoptosis was assessed by double staining using FITC-annexin V and PE-anti-CD3 mAb (*p  0.001 Student’s t test versus
SFCM).
D: Human PBMCs were cultured for 72 hr with PHA in the presence of the indicated stimuli and cell proliferation was assessed by (3H)-thymidine uptake.
Data are expressed as mean (cpm  SD) of triplicate determinations (*p  0.001 Student’s t test versus SFCM).
Blockade of Gal-1 synthesis in tumor cells allows transfectants produced low levels of IL-2 (Figure 5B) and IFN-
(Figure 5C), lymph node cells from mice inoculated with B16the generation of a tumor-specific T1-type
immune response in vivo knockdown transfectants had greatly enhanced B16-specific
T1-type cytokine production. In contrast, no significant differ-The immune regulatory effects of Gal-1 and its ability to skew
the balance of the immune response toward a T2-type profile ences were found in IL-4 (Figure 5D) or IL-5 (Figure 5E) levels
between both experimental groups. These effects were clearly(Rabinovich et al., 1999a) prompted us to investigate whether
resistance to tumor challenge induced by selective Gal-1 block- observed in tumor-draining lymph nodes, but no significant
changes could be detected in lymph nodes distal to tumor sitesade could be associated with an enhancement of a T1-type
antitumor response in vivo. For this purpose, we obtained tu- (Figure 5A and data not shown). Furthermore, we could not
observe changes in T cell proliferation or cytokine secretionmor-draining and distal lymph nodes from mice inoculated with
B16 knockdown or control transfectants. Lymph node cells were when lymph node cells obtained from mice that rejected B16/
C1 transfectants were restimulated ex vivo with syngeneic EL-4restimulated ex vivo with mitomycin C-treated B16 parental cells
and then analyzed for T cell proliferation, cytokine production, thymoma cells (Figures 5A–5E). Thus, selective blockade of
Gal-1 in tumor cells can stimulate the generation of an otherwiseand susceptibility to apoptosis.
Consistent with a role for Gal-1 in tumor-induced immuno- repressed tumor-specific T1-type response in tumor-draining
lymph nodes.suppression, B16/C1 knockdown cells were more effective than
B16/ tumor cells in stimulating an effective T cell-mediated Since Gal-1 contributes substantially to the proapoptotic
activity of melanoma cells (Figure 2), we next investigatedresponse, as demonstrated by the greatly increased tumor-
specific T cell proliferation (Figure 5A). In addition, while tumor- whether tumor-secreted Gal-1 may sensitize T cells in vivo to-
ward an apoptotic phenotype. Tumor-draining lymph nodesdraining lymph nodes from mice inoculated with B16/
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Figure 3. Targeted inhibition of Gal-1 gene expression renders mice resistant to tumor challenge
A: B6 mice were challenged by subcutaneous inoculation of 2  105 parental B16 cells (), control B16/ (), B16/C1 (), B16/C2 (), or B16/C3 ()
transfectants. Tumor growth was monitored every second day (**p  0.001 B16/C1 versus B16/; *p  0.01 B16/C2 and C3 versus B16/ Student’s t test at
day 25 postinoculation). Data represent the mean  SD of at least three different experiments.
B: Kaplan-Meier analysis of mice challenged with control (B16/) or knockdown transfectants (p  0.001 B16/C1 versus B16/; p  0.05 B16/C2 and C3
versus B16/). Results in (A) and (B) summarize data from inoculated B16 clones expressing Gal-1 at low (B16/C1), intermediate (B16/C2, B16/C3), or high
(B16/) levels.
C: In vitro cell growth of parental B16 cells, control (B16/), and knockdown transfectants by the MTT assay.
from mice treated with Gal-1 knockdown transfectants and fur- following treatment with B16/ cells (Figure 5H). Thus, tumor
ther restimulated with parental B16 cells demonstrated a re- rejection induced by Gal-1 blockade is associated with tumor
duced T cell susceptibility to apoptosis compared to lymph cell destruction along with an extensive nonapoptotic mononu-
node cells from mice inoculated with B16/ Gal-1 sufficient clear cell infiltrate, suggesting an increased availability of sur-
tumor cells (Figure 5F). In order to investigate whether the prolif- vival signals influencing the antitumor activity at tumor sites.
erating antitumor cells were capable of infiltrating tumor sites To address whether the generation of a tumor-specific T cell
and promote tumor cell destruction, and to further explore the response in the absence of Gal-1 is sufficient to stimulate pro-
impact of Gal-1 blockade on local immune cell apoptosis, we tective immunity to a subsequent challenge with wild-type B16
performed histopathological analysis and TUNEL staining on tumor cells, we rechallenged mice that had previously rejected
paraffin-embedded tumor sections from B16/ and B16/C1-
B16/C1 transfectants with the corresponding wild-type tumors
treated mice. Ten days after tumor challenge, most peritumoral
20 days after the first exposure. While B16 tumors grew progres-mononuclear cells showed apoptotic morphology (4–7 TUNEL-
sively in naive B6 mice, we observed a significant delay in tumorreactive cells/field, 40) in mice inoculated with B16/ cells,
growth in mice that had been previously exposed to Gal-1compared to mice injected with B16/C1 (0–1 TUNEL-reactive
knockdown transfectants (Figures 6A and 6B).cells/field) (Figures 5G and 5H). In addition, blockade of Gal-1
Taken together, these results demonstrate that selectivewas effective at promoting tumor cell destruction accompanied
inhibition of Gal-1 gene expression in melanoma cells can allowby extensive melanin release at sites of B16/C1 injection,
whereas the integrity of the tumors was completely preserved for and potentiate a tumor-specific T1-type response in synge-
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Figure 4. Tumor rejection induced by Gal-1 blockade requires intact CD4 and CD8 T cell responses
A and B: Selective depletion of lymphocyte subsets was accomplished by intraperitoneal injection of B6 mice with the indicated mAbs at days 1, 1, 8,
15, and 22, relative to tumor inoculation. Mice inoculated with 2  105 B16/C1 cells were treated with the following mAbs: anti-CD4 (), anti-CD8 (), anti-
NK1.1 (), or a combination of anti-CD4 plus anti-CD8 (). Control mice received the equivalent amounts of mouse normal IgG at the same days relative
to inoculation with B16/C1 () or B16/ () transfectants (**p  0.001 depletion of CD4 plus CD8 versus B16/C1 control IgG; *p  0.01 depletion of either
CD4 or CD8 versus B16/C1 control IgG; Student’s t test at day 18 postinoculation).
B: Kaplan-Meier analysis of depleted mice challenged with B16/C1 cells. Results are compiled from two independent experiments (p  0.001 depletion of
CD4 plus CD8 versus B16/C1 control IgG; p  0.05 depletion of CD4 or CD8 versus B16/C1 control IgG).
neic mice, which are then able to resist subsequent challenge responsible for the significant rise in IFN- secretion following
selective blockade of Gal-1 synthesis in tumors. Although CD8with wild-type Gal-1-sufficient tumor cells.
T cells are the cytotoxic effectors in melanoma, CD4 T cells
have been shown to mediate CD8-independent antitumor ef-Discussion
fector functions (Hung et al., 1998). Interestingly, NK cells were
not required to promote tumor rejection in our model. However,Here we demonstrate that tumors can overwhelm T cell effector
functions through Gal-1-dependent mechanisms. By a combi- IFN- production by NK cells was a critical factor in the develop-
ment of antitumor immunity following different stimuli, includingnation of in vitro and in vivo experiments using knockdown
transfectants, we established a link between Gal-1-mediated overexpression of CD70 (Kelly et al., 2002) or NKG2D ligands
(Diefenbach et al., 2001). Thus, the combination of differentimmunoregulation and its contribution to tumor-immune privi-
lege. Blockade of the inhibitory effects of Gal-1 within tumor strategies, stimulating both innate and adaptive immune re-
sponses (Duguay et al., 2002) but also targeting negative regula-tissue resulted in reduced tumor mass and enhanced tumor
rejection, stimulating the generation of a potent tumor-specific tory pathways (Pardoll, 2003), will be necessary to provide com-
plete antitumor protection and allow selective amplification ofT1-type response in syngeneic mice.
During the past few years, there has been increasing ap- immune responses for successful cancer immunotherapy.
An alternative mechanism of enhanced antitumor immunitypreciation for the impact of differential T cell glycosylation in
the modulation of immune responses (Daniels et al., 2002; Feizi, following removal of the inhibitory effects of Gal-1 could be the
emergence of a previously repressed T1-type specific immune2000). Through interaction with poly-N-acetyllactosamine li-
gands, created by specific glycosyltransferases (Nguyen et al., response, as we found greatly increased IFN- production by
lymph node cells from mice inoculated with Gal-1 knockdown2001; Lowe, 2001), Gal-1 influences T cell homeostasis by in-
ducing T cell apoptosis (Rabinovich et al., 1999a), blocking transfectants. This finding strengthens the hypothesis that an
IFN--mediated response is critical to prevent tumor formationT cell activation (Chung et al., 2000), inhibiting proinflammatory
cytokine secretion (Rabinovich et al., 1999b), and favoring turn- and shape tumor immunogenicity (Shankaran et al., 2001; Hu
et al., 1998) and may counteract the gradual loss of TH1 popula-over of activated leukocytes (Dias-Baruffi et al., 2003). There-
fore, the stimulation of an effective antitumor response following tions observed during tumor progression (Ghosh et al., 1995).
Interestingly, we have previously shown that recombinant Gal-1downregulation of Gal-1 could be attributed to several nonexclu-
sive mechanisms. While this effect may be a consequence of and its genetic delivery suppress TH1-mediated inflammation in
experimental models of collagen-induced arthritis and TNBS-the removal of an inhibitory signal involved in T cell death, it is
equally likely to result from the activation of a larger number of induced colitis (Rabinovich et al., 1999a; Santucci et al., 2003).
In these models, Gal-1 administration resulted in a selectivenaive T cells due to a lowering of the threshold for activation.
In this context, Gal-1 blockade may increase both the survival elimination of antigen-activated T cells and in a TH2 shift that
induced a remission state in the evolution of the ongoing in-and frequency of helper and cytotoxic T cells, which could act
in concert to orchestrate the host response against tumors. flammatory disease.
Since Gal-1 was effective at promoting apoptosis of effectorAccordingly, depletion experiments revealed the requirement
for both CD4 and CD8 T cells to promote tumor rejection T cells in autoimmune settings, it may be possible that blockade
of this inhibitory pathway may allow the recruitment and activa-in our model, suggesting that both T cell subsets could be
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Figure 5. Blockade of Gal-1 synthesis in tumor cells allows the generation of a tumor-specific T1-type immune response in vivo
Two weeks after tumor challenge, draining (filled bars) or distal (open bars) lymph nodes were taken from mice inoculated with knockdown (B16/C1) or
control (B16/) transfectants. Lymph node cells (5  105/well) were subjected to restimulation ex vivo with mitomycin C-inactivated B16 tumor cells (5 
105/well) and analyzed for T cell proliferation (A), cytokine production (B–E), and susceptibility to apoptosis (F).
A: After 5 days of restimulation with mitomycin C-treated B16 or EL-4 tumor cells, lymph node cells were pulsed with 1 Ci/ml (methyl-3H) thymidine for the
last 16 hr. Results are expressed as cpm (mean  SD) of triplicate determinations (*p  0.001 B16/C1 versus B16/).
B–E: After 72 hr of restimulation with mitomycin C-treated B16 or EL-4 tumor cells, supernatants were collected from lymph node cells and analyzed for IL-2
(B), IFN- (C), IL-4 (D), and IL-5 (E) production by capture ELISA. Mean values of different groups are indicated (mean  SD) as combination of three
independent experiments (*p  0.001 B16/C1 versus B16/ for IL-2 and IFN-; p  NS B16/C1 versus B16/ for IL-4 and IL-5).
F: Lymph node cells from mice treated with B16/C1 or B16/ transfectants were cultured in the presence of mitomycin C-treated B16 cells for 72 hr. T cell
apoptosis was analyzed by double staining with FITC-annexin V and PE-anti-CD3 mAb (*p  0.05 B16/C1 versus B16/).
G and H: Examination of tumor histopathology and peritumoral mononuclear cell infiltrate in mice injected with B16/C1 or B16/ cells. Palpable tumors or
sites of tumor injection were removed and processed for histological examination in a blinded fashion (Magnification, 40; insets, 100). The number of
apoptotic mononuclear cells (mean  SD) per field (40) was determined in situ by TUNEL assay (*p  0.05 B16/C1 versus B16/; 	2). Insets show apoptotic
(black arrows) or viable (red arrows) mononuclear cells in representative fields. The nuclear staining profile of TUNEL-positive cells (black arrows) is clearly
distinguishable from the irregular and granular aspect of the pigment melanin (M) released by tumors (T).
tion of low-affinity autoreactive T cells that might have escaped The data presented here demonstrate that melanoma cells
may take advantage of Gal-1 expression for inducing apoptosistolerance induction. Although we have not found signs of tissue-
specific self reactivity in our model, a long-term follow up will of tumor-specific effector T cells and that this mechanism may
contribute in tilting the balance toward an immunosuppressivebe necessary to investigate whether mice that rejected chal-
lenge with melanoma transfectants will develop signs of autoim- environment at the tumor site. However, we cannot rule out the
possibility that alternative Gal-1-dependent mechanisms maymune depigmentation, as described for other immunotherapy
strategies (Ramirez-Montagut et al., 2003). contribute to tumor progression. In accordance, previous stud-
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Figure 6. Blockade of Gal-1 synthesis in tumor
cells promotes resistance to subsequent chal-
lenge with wild-type Gal-1-sufficient tumors
A and B: B6 mice that had previously rejected
Gal-1 knockdown transfectants (B16/C1) were
inoculated in the opposite flank 20 days after the
first tumor challenge with wild-type B16 tumor
cells (2 105). Age-matched naive B6 mice were
challenged in parallel with the same number of
tumor cells. Tumor size was monitored every sec-
ond day and mice were sacrificed when tumor
size reached 2 cm3. *p  0.001 B16/C1 versus
naive mice; Student’s t test at day 28 postinocu-
lation (A); p  0.002 B16/C1 versus naive mice;
Kaplan-Meier analysis (B).
Generation of knockdown tumor clonesies show that Gal-1 may affect homotypic cell aggregation (Ti-
Murine Gal-1 cDNA (length 495 bp) was obtained from the IMAGE Consor-nari et al., 2001), adhesion (van den Brule et al., 1995), migration
tium (MRC, Cambridge) and subcloned immediately downstream of the(Camby et al., 2001), and tumor cell proliferation (Kopitz et
cytomegalovirus (CMV) promoter of a HindIII/BamH1-cut pcDNA3 expres-
al., 2001) in vitro. Furthermore, since human tumors express a sion vector (Invitrogen) as described (Rabinovich et al., 1999a). A clone in
complex pattern of galectin expression (Lahm et al., 2001), fu- the antisense orientation was obtained from pcDNA3-Gal-1, excised with
ture studies are warranted to elucidate the immunoregulatory BamH1 and EcoRV, and subcloned into the CMV-driven pcDNA6 expression
vector (Invitrogen) to create the plasmid p6/G1-As.properties of other members of the galectin family (Fukumori et
Subconfluent B16 cells were transfected with p6/G1-As using Lipofec-al., 2003) and their contribution to tumor-immune privilege.
tamine 2000 (Life Technologies). Blasticidine-resistant (5 g/ml, ICN) stableThe hypothesis of “tumor counterattack” suggests that tu-
transfectants were cloned by limited dilution, and 12 clones were generated.
mors may deliver death signals to Fas-sensitive effector cells, Representative clones with low (B16/C1) or intermediate (B16/C2; C3) Gal-1
thus rendering the tumor an immunologically privileged site levels were selected for in vitro and in vivo experiments. B16 cell lines
(O’Connell et al., 2001). Although this model has not been uni- transfected with vector alone (B16/) were used as controls. Stable transfec-
tants and controls were screened for Gal-1 expression and secretion byversally accepted, recent studies highlight the contribution of
flow cytometry and Western blot analysis.novel tumor-associated molecules to tumor-immune evasion,
including B7-H1 (Dong et al., 2002) and the enzyme indoleamine
Western blot analysis2,3 dioxigenase (IDO) (Uyttenhove et al., 2003; Friberg et al.,
Human and murine melanoma cell lines and different knockdown clones
2002). Furthermore, accumulating evidence indicates that (1.5  106 cells) were extensively washed and lysed in 100 l lysis buffer
blocking different inhibitory signals such as CTLA-4 (Phan et (5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.15 M
NaCl, 50 mM Tris-HCl) in the presence of a mixture of protease inhibitorsal., 2003), Stat3 (Cheng et al., 2003), or TGF-
 (Gorelik and
(Sigma). SFCM were collected from 18 h-semiconfluent melanoma cell cul-Flavell, 2001) may be effective alone or in combination with
tures, centrifuged at 1000 g for 5 min to discard cell debris, and storedother immunotherapy strategies to break immunological toler-
frozen at 70C. Proteins were precipitated with 9 vol of methanol overnightance and promote tumor regression (Boon and van den Eynde,
at 20C. Human melanoma tissue samples were obtained from the Pathol-
2003). ogy Department, Hospital Eva Pero´n, with approval of the Institutional Review
Taken together, our results provide evidence both in vitro Board, and total tissue extracts were prepared as described (Xu et al., 1995).
and in vivo showing that Gal-1 contributes to immune privilege Protein concentration was measured using the Micro-BCA kit (Pierce).
Equal amounts of protein of cell lysates and supernatants (15 g) wereof tumors by modulating survival and/or polarization of effector
resolved on a 15% SDS-PAGE. After electrophoresis, the separated proteinsT cells, providing a link between the immunoregulatory proper-
were electroblotted onto polyvinylidene difluoride (PVDF) membranes (Amer-ties of this protein and its contribution to tumor progression.
sham) and probed with a 1:4000 dilution of an affinity-purified rabbit anti-
More importantly, our data highlight a novel molecular target Gal-1 Ab (kindly provided by Drs. J. Hirabayashi and K.I. Kasai) or the
for manipulation of T cell tolerance and apoptosis with profound same dilution of a control preimmune IgG. Blots were then incubated with
implications for cancer immunotherapy. a peroxidase-labeled anti-rabbit IgG (BioRad) and developed using an en-
hanced chemoluminescence detection kit (Amersham). Films were analyzed
Experimental procedures with the Scion Image Analysis software, and the intensity of each band was
recorded and expressed as arbitrary units (AU). Recombinant Gal-1 (rGal-1)
Tumor cell lines was used as a positive control of immunodetection. Equal loading was
The human melanoma cell lines IIB-Mel-LES, IIB-Mel-J, and IIB-Mel-IAN checked by Ponceau S staining or by incubation of the blots with an anti-
were established from human metastatic melanomas as described (Guerra tubulin mAb (Sigma).
et al., 1989; Kariyama et al., 1995; Ledda et al., 1997), SKMel28 was obtained
from ATCC, and the A375N cell line was a gift from Dr. E. Medrano. The Immunofluorescence staining and confocal microscopy
murine B16 melanoma cell line was obtained from ATCC and the EL-4 Tumor cells were washed twice in PBS and fixed in 2% paraformaldehyde
for 15 min on ice. Cells were then stained with a 1:500 dilution of a rabbitthymoma was a gift from Dr. C. Milstein. Both murine cell lines are syngeneic
anti-Gal-1 Ab (or control rabbit IgG) for 30 min on ice and then incubatedto C57BL/6 (B6) background.
with a FITC-conjugated goat anti-rabbit IgG (Cappel). In each experiment,
104 viable cells were processed for FACS analysis in a FACSCalibur flowMice
Eight- to ten-week-old inbred female C57BL/6 (H-2b) mice were used in cytometer (Becton Dickinson). For confocal microscopy, tumor cells were
cultured overnight on glass coverslips washed with PBS, fixed with 4%this study. Animals were maintained at the Animal Resource Facilities (Insti-
tute Leloir) in accordance with the experimental ethics committee guidelines. paraformaldehyde for 10 min, permeabilized using PBS containing 0.2%
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Triton X-100, and stained as described above, except that donkey anti- In vivo lymphocyte subset depletion
rabbit Cy2 (Jackson) was used as secondary Ab. Color confocal and trans- CD4, CD8, or NK1.1 cells were depleted in vivo by intraperitoneal admin-
mitted light images were acquired with the use of a Zeiss LSM 510 micro- istration of 0.2 mg of mAbs against CD4 (clone YTS 191.1; ATCC), CD8
scope (Jena, Germany) with C-apochromat 63/1.2 W objective. The image (clone YTS 169.4; ATCC), or NK1.1 (clone 4D11; ATCC) at days 1, 1, 8,
size was set to 1024 pixels with 8 bits pixel depth. 15, and 22, relative to tumor inoculation as described (Diefenbach et al.,
2001). Control mice received equivalent amounts of normal mouse IgG at
Protein purification and amino acid sequence analysis the same days. Depletions were confirmed in lymph nodes and spleen cells
Serum-free culture medium was collected from semiconfluent monolayers 7 days after tumor challenge by flow cytometry using non crossreactive Abs.
of Mel-J or Mel-LES cell lines, processed as described (Morvillo et al., 1996), In general, less than 1.7% of the depleted cell population could be detected
and subjected to size-exclusion chromatography (Superose 12HR 10/30 in spleen and lymph nodes, whereas mice treated with control IgG demon-
column, Pharmacia). The eluted low molecular weight fraction was concen- strated unchanged lymphocyte profiles. Kaplan-Meier analysis was per-
trated and applied to a lactosyl-Sepharose column (Sigma) to enrich for formed as described above. Results are expressed as mean  SD from two

-galactoside binding proteins. After elution with lactose, one major peak independent experiments with n  5 mice in each group per experiment.
was obtained, which was subjected to trypsin digestion and amino acid
sequence analysis, as described (Rabinovich et al., 1998). Tryptic peptides In situ TUNEL labeling, histopathology,
were separated by reverse phase HPLC on a Brownlee C18 column, applied and immunohistochemistry
to a Polybrene-coated glass filter, and sequenced in an Applied Biosystems Ten days after tumor challenge, palpable tumors of mice inoculated with
model 477A automatic sequencer. B16/ or sites of tumor injection of mice inoculated with B16/C1 were
removed, paraffin-embedded, and processed for histological examination
Lymphocyte preparation and activation and apoptosis detection by a peroxidase-conjugated in situ TUNEL assay
Splenocytes from B6 mice were prepared by mechanical disruption of (Intergen) according to the manufacturer’s instructions. Representative tis-
spleens using standard protocols. For apoptosis assays, splenocytes (5  sue samples for each treatment were also stained with hematoxylin and
106 cells/ml) were activated with Con A (5 g/ml) for 72 hr and then cultured eosin. Qualitative and quantitative studies of stained sections were per-
for 18 hr in the absence or presence of optimal dilutions (1:2) of SFCM formed in a blinded fashion by a medical pathologist on five or more samples
derived from an equal cell number of knockdown or control transfectants. from distinct mice, and the number of TUNEL-reactive mononuclear cells
Human PBMCs were isolated from healthy donors by Ficoll-Paque Plus per field (40) was recorded. Immunoperoxidase staining was performed
(Amersham) gradient centrifugation, washed, and resuspended in complete on paraffin-embedded tissue sections from human melanoma samples using
RPMI 1640 medium. Cells (1  106 cells/ml) were then stimulated for 72 hr the anti-Gal-1 Ab (1:500) or the same dilution of a control rabbit IgG. The
with 1 g/ml PHA (Sigma) and further cultured for 18 hr in the presence of avidin-biotin peroxidase complex was used according to the manufacturer’s
optimal dilutions of SFCM (1:2) collected from human Mel-J and Mel-LES recommended instructions (ABC Vectastatin, Vector).
cell lines. In neutralization experiments, melanoma cell supernatants were
added to PBMCs in the presence of 30 mM TDG (Sigma) or saturating MTT assay
amounts (10 g/ml) of a blocking anti-Gal-1 IgG (Fab)2 prepared using the Tumor cell growth in vitro was measured by the colorimetric MTT assay.
Immobilized Pepsin kit (Pierce) or (Fab)2 fragment of a control rabbit IgG. Briefly, exponentially growing control or knockdown transfectants were thor-
After incubation with different stimuli, cells were washed with sterile PBS
oughly washed and incubated for 24 hr in serum-free medium to synchronize
containing 30 mM lactose to dissociate cell clusters and processed for
cell growth. Thereafter, 103 cells/well were cultured in 96-well plates in
apoptosis detection. As control of Gal-1-induced apoptosis, activated
complete DMEM. Cell growth was determined at 24 hr intervals by replacing
PBMCs were exposed to different doses of rGal-1 as described (Rabinovich
the culture medium with 0.1 ml of MTT solution (Sigma). Cell lines were then
et al., 2002b). To analyze cell proliferation, PBMCs were cultured for 72 hr
incubated at 37C for 2 hr and exposed to 200 l of solubilizer solution (90%
either with PHA (1 g/ml) or an anti-CD3 mAb (25 ng/ml; Becton Dickinson)
isopropanol, 20% DMSO, 4% Tween 20), and absorbance was determined at
in the presence of the indicated stimuli. Then cultures were pulsed with 1
562 nm.
Ci/ml (methyl-3H) thymidine (specific activity 50 Ci/mmol; New England
Nuclear) for the last 16 hr. Results are expressed as cpm  SD of triplicate
Ex vivo analysis of T cell proliferation and apoptosisdeterminations.
Tumor-draining or distal lymph nodes were obtained from mice injected with
knockdown or control transfectants 2 weeks after tumor challenge. LymphApoptosis assays
node cells were prepared using standard protocols and analyzed for T cellT cell apoptosis was evaluated by a double staining procedure using the
proliferation, cytokine production, and susceptibility to apoptosis. Briefly,FITC-annexin V binding assay (Immunotech) and PE-conjugated anti-CD3
cells (5  105/well) were stimulated in RPMI 1640 complete medium withmAb. The percentage of nuclei with subdiploid DNA content was determined
mitomycin C-treated B16 parental cells (5 105/well) or mitomycin C-treatedby propidium iodide (PI) staining. Briefly, cells were gently resuspended in
EL-4 cells (5  105/well). After 5 days, cultures were pulsed with 1 Ci/ml1 ml hypotonic fluorochrome solution (50 g/ml PI diluted in 0.1% sodium
(methyl-3H) thymidine (specific activity 50 Ci/mmol; New England Nuclear)citrate plus 0.1% Triton X-100) and kept at 4C for 3 hr in the dark. Ten
for the last 16 hr. Incorporation of radioactivity was measured in a liquidthousand events were acquired in a FACSCalibur flow cytometer.
scintillation 
-counter (Packard Instruments) and expressed as cpm  SD
of triplicate determinations. Susceptibility to apoptosis was assessed byIn vivo tumor challenge
annexin V and PI staining, following restimulation of lymph node cells withMelanoma tumors were established in B6 mice by subcutaneous injection
mitomycin C-inactivated B16 cells for 72 hr.of 2  105 cells in 50 l of sterile PBS into the right flank. Mice were
challenged with B16/ transfectants (n  21; seven mice per experiment)
Cytokine assaysor independent knockdown clones (n  27; nine mice per experiment).
Lymph node cells (5 105/well) taken from mice inoculated with knockdownRepresentative clones used for challenge were selected on the basis of
or control transfectants were restimulated with or without mitomycinGal-1 expression. Tumor development was monitored every second day by
C-inactivated B16 (5  105/well) or EL-4 cells (5  105/well). After 72 hr, cell-measuring tumor perpendicular diameters with a metric caliper. Tumor vol-
free supernatants were collected and subjected to cytokine determinationume was estimated as (d2  D  0.5), where d and D are the minor and
(IFN-, IL-2, IL-4 and IL-5) using specific capture ELISA kits (Pharmingen),major diameters, respectively. For ethical reasons, animals were sacrificed
according to the manufacturer’s instructions. Data are given as the meanwhen tumors reached a volume greater than 2 cm3. Mice with tumor volume
of triplicate measurements of three independent experiments.less than 0.5 cm3 were considered as tumor free for the Kaplan-Meier analy-
sis. For rechallenge experiments, groups of five mice that had completely
Statistical analysisrejected the initial tumor (20 days after first inoculation) were injected in the
Comparison of two groups was made using Student’s t test for unpaired dataopposite flank with wild-type B16 tumor cells. Age-matched naive mice
injected with B16 tumor cells were used as controls. when appropriate. Kaplan-Meier analysis was used to establish statistical
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Duguay, D., Mercier, F., Stagg, J., Martineau, D., Bramson, J., Servant, M.,significance for in vivo experiments. The chi-square (	2) test was used for
Galipeau, J., and Hiscott, J. (2002). In vivo IRF-3 tumor suppressor activityanalysis of histological data.
in B16 melanoma tumors. Cancer Res. 62, 5148–5152.
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